Back

City Therapeutics prepares U.S. IPO to fund RNAi pipeline

Verifying
  • City Therapeutics is preparing a U.S. IPO to fund its RNAi therapeutic pipeline.
  • CITY-FXI is the company’s lead candidate aimed at treating thrombosis.
  • City Therapeutics has reported promising early Phase 1 results and partner support.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.